In:
Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 144, No. Suppl_1 ( 2021-11-16)
Abstract:
Objectives: Investigate if the amount of reverse remodelling after CRT coincides with blood biomarker changes. Background: Blood biomarkers are predictors of heart failure, but sparse data exist on the correlation between blood biomarkers changes and reverse remodelling. Methods: Fourteen blood biomarkers, reflecting collagen turnover (PIIINP, CICP, MMP-9, TIMP-1, ICTP), inflammation (hsCRP, IL-6), myocardial stretch and injury (NT-proBNP, hsTroponin-T), inflammatory-, fibrotic- and apoptotic pathways (Galectin-3, ST2, GDF-15) and renal function (creatinine, BUN), were assessed before and six months after CRT in 213 patients from the Markers and Response to CRT study. Additionally, baseline peripheral venous (PV) and coronary sinus (CS) samples were compared. Patients were divided in 4 groups based on indexed left ventricular end systolic volume change (LVESVi): no remodelling, lower, middle, and upper tertile. Results: Mean age was 66±10 years, 62% were men, 42% had ischemic aetiology. 169 patients experienced LVESVi reduction: lower tertile 12% (5-16%), middle tertile 32% (25-37%), upper tertile 53% (44-58%). Collagen markers increased in all groups. Inflammation markers remained in normal range. hsTroponin-T decreased in all groups. Renal markers showed no clinical significant change. GDF-15, ST2 and Galectin-3 remained elevated, showing no distinct pattern. Only NT-proBNP changes corresponded to LVESVi reduction (β -1.72, P 〈 0.001). Between all CS-PV samples was a positive correlation (R-range: 0.72-0.97, all P 〈 0.001). Conclusions: NT-proBNP changes are associated with amount of reverse remodelling 6 months after CRT. Thirteen other blood biomarkers, reflecting, among others, collagen turnover, fibrotic- and apoptotic pathways, are not. CS and PV samples correspond well, CS sampling does not seem to provide additional information in assessing reverse remodelling.
Type of Medium:
Online Resource
ISSN:
0009-7322
,
1524-4539
DOI:
10.1161/circ.144.suppl_1.12543
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
1466401-X
Bookmarklink